Article
A Bridge to Capacity for the Cell & Gene Industry
Ravi Samavedam
In this Outsourced Pharma article, you will gain insight into the rapidly growing cell and gene therapy market and how to stay on top of the increased manufacturing demand.
Chief Editor of Outsourced Pharma, Louis Garguilo, interviews Azzur Group's Chief Innovation Officer, Ravi Samavedam, on an innovative model that provides fully outfitted GxP capacity designed to accelerate manufacturing capabilities.
“What separates us from the CDMO model is we do not make the product for our clients, CDMOs are not direct competitors of ours. We have clients that are CDMOs.”
- Ravi Samavedam, Chief Innovation Officer at Azzur Group
Read the full article featured on Outsourced Pharma or learn more about the unique hybrid model, Azzur Cleanrooms on Demand™, that is accommodating the growth in the Life Sciences market.
Ravi Samavedam
Ravi Samavedam joined Azzur Group in 2012 and is a Biochemical Engineer with more than 20 years of experience. Prior to his appointment to Chief Innovation Officer (CINO), Ravi served as President of Azzur Cleanrooms on Demand™ and previously was a General Manager of Azzur Boston. Ravi has been a part of technical operations, quality, and validation departments at some of the world’s foremost pharmaceutical manufacturers. He is an expert in phase-appropriate cGMP implementation, process validation, supplier management, and technology transfer. Ravi is an active member of industry and peer groups, and he is a frequent speaker at industry events.
Connect On Linkedin